GO:0035500 MH2 domain binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035500 (MH2 domain binding) is a molecular function describing the binding of a protein to an MH2 (MAD homology 2) domain, a carboxy-terminal domain found in MAD-related proteins such as Smads.
• The MH2 domain mediates interaction with a wide variety of proteins and provides specificity and selectivity to Smad function, and is also critical for mediating interactions in Smad oligomers.
• MH2 domain interactions are central to TGF-β superfamily signaling, controlling transcription, proliferation, and differentiation.
• Dysregulated MH2 domain binding contributes to fibrosis, cancer, and chronic inflammatory diseases such as COPD.
• Key genes whose products bind the MH2 domain include SMAD2, SMAD3, SMAD4, TGIF1, SARA, p300, pVHL, and PKM2.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of MH2 domain interactions in disease.
Description
GO:0035500, MH2 domain binding, is a molecular function term that describes the binding of a protein to an MH2 (MAD homology 2) domain. The MH2 domain is found at the carboxy-terminus of MAD-related proteins such as Smads, and it mediates interaction with a wide variety of proteins while providing specificity and selectivity to Smad function; it is also critical for mediating interactions in Smad oligomers. Because Smad proteins are the principal intracellular transducers of TGF-β superfamily signals, proteins that bind the MH2 domain act as essential modulators of signaling output. Researchers study MH2 domain binding to understand how extracellular cues are converted into transcriptional programs. For example, the MH2 domain of SMAD2 binds TGIF1, and structural analysis has revealed the molecular basis of this interaction. In pulmonary epithelium, the MH2 domain of Smad3 is the target of covalent modification by ligustilide, which disrupts the Smad3-SARA interaction and attenuates airway remodeling. Similarly, PKM2 stabilizes TGF-β1 receptor I and enhances TGF-β1 signaling, illustrating how MH2-domain-associated complexes influence fibrosis. Dysregulation of MH2 domain binding is implicated in cancer and fibrotic disease. SMAD4 modulation by HBx is required for proliferation in hepatitis B-related liver cancer, and the SMAD3-p300 complex scaffolded by the long non-coding RNA LIMD1-AS1 promotes TGF-β-induced breast cancer cell plasticity. pVHL-mediated degradation of SMAD3 suppresses TGF-β signaling, providing a further layer of control. Thus, GO:0035500 defines a functionally critical interface that is both a research focus and a potential therapeutic target.
MH2 domain binding At A Glance
| GO ID | GO:0035500 |
|---|---|
| GO term | MH2 domain binding |
| Ontology | molecular_function |
| Synonym | MAD homology 2 domain binding |
| Definition | Binding to a MH2 (MAD homology 2) protein domain. The MH2 domain is found at the carboxy-terminus of MAD related proteins such as Smads. The MH2 domain mediates interaction with a wide variety of proteins and provides specificity and selectivity to Smad function and also is critical for mediating interactions in Smad oligomers. |
| Major function | Mediates protein-protein interactions that regulate Smad-dependent TGF-β superfamily signaling and Smad oligomerization. |
| Domain location | Carboxy-terminus of MAD-related proteins such as Smads. |
| Representative binders | TGIF1, SARA, p300, pVHL, PKM2, and other Smad-interacting proteins. |
| Disease relevance | Fibrosis, cancer, and chronic inflammatory airway disease. |
What Is GO:0035500?
In our own words, GO:0035500 (MH2 domain binding) is the molecular function of selectively and non-covalently interacting with an MH2 domain, a compact carboxy-terminal domain characteristic of MAD-related proteins such as Smads. The MH2 domain serves as a protein-protein interaction module that confers specificity and selectivity to Smad function and is essential for Smad oligomerization.
Why Is MH2 domain binding Important in Cell Biology?
MH2 domain binding is important because it defines the interaction surface through which Smad proteins recruit cofactors, scaffolds, and modifying enzymes to control TGF-β superfamily signaling. Structural and biochemical studies show that the MH2 domain provides specificity and selectivity to Smad function and is critical for Smad oligomerization. Disruption or enhancement of these interactions alters transcription, proliferation, and differentiation, with direct consequences for fibrosis, cancer, and inflammatory disease.
• Defines the interaction interface for Smad oligomerization and cofactor recruitment.
• Controls TGF-β superfamily signaling output, affecting transcription and cell fate.
• Implicated in pulmonary fibrosis through PKM2 stabilization of TGF-β1 receptor I.
• Targeted by small molecules such as ligustilide to disrupt Smad3-SARA interaction in COPD airway remodeling.
• Linked to cholangiocarcinoma through AMDHD1-mediated activation of TGF-β signaling.
• Modulated in hepatitis B-related liver cancer via HBx-dependent SMAD4 regulation.
• Contributes to breast cancer cell plasticity through SMAD3-p300 scaffolding by LIMD1-AS1.
• Regulated by pVHL-mediated SMAD3 degradation, suppressing TGF-β signaling.
• Provides a structural template for designing inhibitors of Smad-protein interactions.
• Enables CRISPR-based causal studies of Smad complex components in disease models.
MH2 domain binding: mechanism, structure, and regulation
What Happens During MH2 domain binding?
In simple terms: When a protein binds an MH2 domain, it plugs into a specialized docking site on Smad proteins and changes how signals are passed inside the cell.
MH2 domain binding occurs when a partner protein recognizes the carboxy-terminal MH2 domain of a MAD-related protein such as a Smad. The MH2 domain mediates interaction with a wide variety of proteins and provides specificity and selectivity to Smad function, and it is also critical for mediating interactions in Smad oligomers. Structural analysis of the human TGIF1-SMAD2 MH2 domain complex has revealed the molecular details of this binding event. In pulmonary epithelium, the MH2 domain of Smad3 is covalently modified by ligustilide, which disrupts the Smad3-SARA interaction and attenuates airway remodeling. These examples show that MH2 domain binding is a dynamic step that can be modulated by small molecules and by cellular context.
Smad oligomerization and complex assembly
In simple terms: Smad proteins hold onto each other through their MH2 domains to form the working signaling machines.
The MH2 domain is critical for mediating interactions in Smad oligomers. Crystallographic analysis of the MH2 domain of Drosophila Mad provided early structural evidence for how this domain supports oligomerization. In human cells, SMAD3 and p300 form a complex scaffolded by the long non-coding RNA LIMD1-AS1, which promotes TGF-β-induced breast cancer cell plasticity. SMAD4 is also a central component of these complexes, and its spatiotemporal modulation by HBx is required for cellular proliferation in hepatitis B-related liver cancer. Together, these findings indicate that MH2 domain binding underlies the assembly of higher-order Smad complexes that drive transcriptional responses.
Structure and Composition of MH2 domain binding
In simple terms: The MH2 domain is a compact protein module at the tail end of Smads that acts like a multi-purpose connector.
The MH2 domain is found at the carboxy-terminus of MAD-related proteins such as Smads. Its structure supports binding to diverse partners, including transcriptional cofactors and scaffolding proteins. The crystal structure of the MH2 domain of Drosophila Mad has been determined, providing a template for understanding how this domain mediates interactions. In the human system, the structure of TGIF1 bound to the SMAD2 MH2 domain has been solved, revealing the interface that confers specificity. These structural data show that the MH2 domain is not a passive tail but an organized interaction module.
Molecular Mechanism of MH2 domain binding
In simple terms: Binding to the MH2 domain works like a lock-and-key plus a switch: it selects partners and changes signaling activity.
At the molecular level, MH2 domain binding provides specificity and selectivity to Smad function and is critical for mediating interactions in Smad oligomers. The interaction can be disrupted by small molecules: ligustilide covalently binds the MH2 domain of Smad3 and disrupts the Smad3-SARA interaction, attenuating airway remodeling in COPD mice. Binding partners can also regulate Smad stability; pVHL mediates SMAD3 degradation and thereby suppresses TGF-β signaling. In addition, PKM2 stabilizes TGF-β1 receptor I and enhances TGF-β1 signaling, showing that MH2-domain-associated complexes are integrated with receptor-level control. These mechanisms illustrate how a single domain-binding event can be translated into changes in transcription and cell behavior.
Regulation of MH2 domain interactions
In simple terms: Cells tune MH2 domain binding up or down by degrading, modifying, or scaffolding the Smad proteins involved.
MH2 domain interactions are regulated at multiple levels. pVHL-mediated degradation of SMAD3 suppresses TGF-β signaling, providing a degradation-dependent control mechanism. The long non-coding RNA LIMD1-AS1 scaffolds the SMAD3 and p300 complex, promoting TGF-β-induced breast cancer cell plasticity. In hepatitis B-related liver cancer, spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation. AMDHD1 acts as a tumor suppressor and contributes to activation of the TGF-β signaling pathway in cholangiocarcinoma, further linking MH2-domain-associated signaling to disease. These examples show that regulation occurs through protein stability, non-coding RNA scaffolding, and viral proteins.
Key Genes Involved in GO:0035500 MH2 domain binding
The following genes and proteins are experimentally implicated in MH2 domain binding or in complexes that depend on MH2 domain interactions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMAD2 | MH2 domain-containing signal transducer; binds TGIF1 | Structural studies of TGIF1-SMAD2 MH2 complex |
| SMAD3 | MH2 domain-containing signal transducer; binds SARA and p300 | Target of ligustilide; scaffolded by LIMD1-AS1; degraded by pVHL |
| SMAD4 | Common Smad involved in Smad oligomers | Modulated by HBx in hepatitis B-related liver cancer |
| TGIF1 | Transcriptional repressor that binds SMAD2 MH2 domain | Structural insights into binding interface |
| SARA | Scaffolding protein that interacts with Smad3 MH2 domain | Disrupted by ligustilide in COPD airway remodeling |
| p300 | Transcriptional coactivator in SMAD3 complex | Scaffolded by LIMD1-AS1 in breast cancer plasticity |
| pVHL | E3 ubiquitin ligase that mediates SMAD3 degradation | Suppresses TGF-β signaling |
| PKM2 | Kinase that stabilizes TGF-β1 receptor I | Promotes pulmonary fibrosis |
| AMDHD1 | Tumor suppressor linked to TGF-β activation | Cholangiocarcinoma |
| HBx | Viral protein that modulates SMAD4 | Hepatitis B-related liver cancer |
| LIMD1-AS1 | Long non-coding RNA scaffold | Promotes TGF-β-induced breast cancer cell plasticity |
| Mad (Drosophila) | MH2 domain-containing Smad ortholog | Crystal structure of MH2 domain |
| TGF-β1 receptor I | Receptor stabilized by PKM2 | Pulmonary fibrosis |
| SMAD oligomers | Complexes formed via MH2 domain interactions | Critical for Smad function |
How Is MH2 domain binding Regulated?
MH2 domain binding is regulated by protein degradation, non-coding RNA scaffolding, and viral proteins. pVHL-mediated degradation of SMAD3 suppresses TGF-β signaling. The long non-coding RNA LIMD1-AS1 scaffolds the SMAD3 and p300 complex to promote TGF-β-induced breast cancer cell plasticity. In hepatitis B-related liver cancer, spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation. AMDHD1 contributes to activation of the TGF-β signaling pathway in cholangiocarcinoma. These mechanisms collectively tune the availability and composition of MH2-domain-containing complexes.
MH2 domain binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMAD3 | COPD airway remodeling; breast cancer plasticity | Smad3 knockout or point-mutant pulmonary epithelial cells; LIMD1-AS1 perturbation |
| PKM2 | Pulmonary fibrosis | PKM2 knockout or overexpression in lung fibroblasts |
| SMAD4 | Hepatitis B-related liver cancer | HBx-expressing hepatocyte models with SMAD4 knockout or knock-in |
| AMDHD1 | Cholangiocarcinoma | AMDHD1 knockout or overexpression in cholangiocarcinoma cell lines |
| pVHL | TGF-β signaling suppression | pVHL knockout or point-mutation in cancer cell lines |
Pulmonary fibrosis and COPD
PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling, linking MH2-domain-associated signaling to fibrotic lung disease. In COPD mice, ligustilide attenuates airway remodeling by covalently binding the MH2 domain of Smad3 in pulmonary epithelium and disrupting the Smad3-SARA interaction. These studies show that MH2 domain binding is a druggable node in chronic lung disease.
Cancer
AMDHD1 acts as a tumor suppressor and contributes to activation of the TGF-β signaling pathway in cholangiocarcinoma. In hepatitis B-related liver cancer, spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation. The SMAD3 and p300 complex scaffolded by long non-coding RNA LIMD1-AS1 promotes TGF-β-induced breast cancer cell plasticity. pVHL-mediated SMAD3 degradation suppresses TGF-β signaling, providing a tumor-suppressive control point. Together, these findings implicate MH2 domain binding in multiple cancer types.
Structural basis for therapeutic targeting
Structural insights into the binding of human TGIF1 with the SMAD2 MH2 domain provide a template for rational design of inhibitors. The crystal structure of the MH2 domain of Drosophila Mad further informs comparative and evolutionary analysis of this interaction module. Small-molecule disruption of MH2 domain binding, as demonstrated with ligustilide, supports the feasibility of targeting this interface.
From MH2 domain binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SMAD3 MH2 domain binding reduce TGF-β transcriptional output? | SMAD3 knockout or MH2 point-mutation cell lines |
| Can a disease-associated mutation in SMAD4 alter Smad oligomerization? | SMAD4 point-mutation knock-in models |
| Does PKM2 stabilization of TGF-β1 receptor I require MH2 domain interactions? | PKM2 knockout and overexpression in lung cells |
| Is AMDHD1-dependent TGF-β activation mediated by MH2 domain complexes? | AMDHD1 knockout and rescue with tagged knock-in |
| Does pVHL-mediated SMAD3 degradation depend on the MH2 domain? | pVHL knockout with SMAD3 point mutants |
| Can small molecules disrupt Smad3-SARA interaction? | Tagged knock-in Smad3 reporter cells treated with ligustilide |
How to Study the MH2 domain binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Atomic structure of MH2 domain complexes | Determining binding interfaces |
| Co-immunoprecipitation | Protein-protein interactions | Validating MH2 domain binding partners |
| Reporter assays | TGF-β transcriptional activity | Linking MH2 domain binding to signaling output |
| Affinity purification-mass spectrometry | Interactome composition | Identifying MH2 domain binders |
| CRISPR knockout | Loss-of-function effects | Testing causal roles of Smad components |
| CRISPR point mutation | Specific residue contributions | Dissecting MH2 domain interfaces |
| CRISPR knock-in | Tagged or mutant protein expression | Tracking endogenous complexes |
| Overexpression | Gain-of-function effects | Testing oncogenic or fibrotic drivers |
Structural biology and binding assays
Crystallography and related structural methods have been used to determine the MH2 domain of Drosophila Mad and the human TGIF1-SMAD2 MH2 complex. These approaches define the atomic interface and guide mutagenesis. Binding assays such as co-immunoprecipitation and pull-down can validate interactions predicted from structures.
Transcriptional and signaling readouts
TGF-β signaling output can be measured using reporter assays and expression profiling of Smad target genes. Studies of SMAD3-p300 scaffolding by LIMD1-AS1 and SMAD4 modulation by HBx used such readouts to link MH2 domain complexes to transcription. These methods are essential for connecting binding events to functional outcomes.
Proteomics and interactomics
Affinity purification coupled to mass spectrometry can identify proteins that bind the MH2 domain. This approach complements structural studies and can reveal context-dependent partners such as p300, pVHL, and PKM2. Quantitative proteomics can also measure changes in Smad complex composition after perturbation.
CRISPR-based perturbation
CRISPR knockout, point mutation, knock-in, and overexpression enable causal testing of MH2 domain binding. For example, disrupting the Smad3-SARA interaction with ligustilide was studied in COPD models, and SMAD4 modulation by HBx was examined in liver cancer cells. These approaches can be combined with structural and proteomic readouts.
How CRISPR Can Be Used to Study GO:0035500 MH2 domain binding
Knockout
CRISPR knockout of genes encoding MH2 domain-containing proteins or their binding partners can reveal loss-of-function phenotypes. For example, knocking out SMAD3 or its partners can test effects on TGF-β signaling and airway remodeling. Knockout of pVHL can stabilize SMAD3 and alter signaling output.
Point Mutation
Point mutations in the MH2 domain or in binding interfaces can dissect specific residue contributions. This is valuable for understanding how TGIF1 binds the SMAD2 MH2 domain and how SMAD4 modulation by HBx affects proliferation. Point mutants can also test whether covalent modification sites in Smad3 are required for ligustilide effects.
Knock-in
Knock-in of tagged or mutant alleles allows tracking of endogenous MH2 domain complexes. Tagged SMAD3 or SMAD4 can be used to monitor complex assembly and localization. Knock-in of disease-associated variants can model altered MH2 domain binding in cancer or fibrosis.
Overexpression
Overexpression of MH2 domain-containing proteins or their partners can drive gain-of-function phenotypes. PKM2 overexpression enhances TGF-β1 signaling and promotes pulmonary fibrosis, while AMDHD1 overexpression can activate TGF-β signaling in cholangiocarcinoma models. These models complement knockout studies.
How EDITGENE Supports MH2 domain binding Research
Researchers studying MH2 domain binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling or disease phenotype. EDITGENE provides CRISPR-based cell model services that enable precise, reproducible interrogation of MH2 domain interactions.
Contact EDITGENE today to design your custom CRISPR model for MH2 domain binding research.
Frequently Asked Questions About MH2 domain binding
What is MH2 domain binding?
MH2 domain binding (GO:0035500) is the molecular function of binding to an MH2 (MAD homology 2) protein domain, which is found at the carboxy-terminus of MAD-related proteins such as Smads and mediates interactions with a wide variety of proteins.
What genes are involved in MH2 domain binding?
Genes and proteins implicated include SMAD2, SMAD3, SMAD4, TGIF1, SARA, p300, pVHL, PKM2, AMDHD1, and the Drosophila Mad protein.
What is the function of the MH2 domain?
The MH2 domain mediates interaction with a wide variety of proteins, provides specificity and selectivity to Smad function, and is critical for mediating interactions in Smad oligomers.
How is MH2 domain binding regulated?
It is regulated by protein degradation, such as pVHL-mediated SMAD3 degradation, by non-coding RNA scaffolding such as LIMD1-AS1, and by viral proteins such as HBx.
Which diseases are linked to MH2 domain binding?
MH2 domain binding has been linked to pulmonary fibrosis, COPD airway remodeling, cholangiocarcinoma, hepatitis B-related liver cancer, and breast cancer cell plasticity.
Can small molecules target MH2 domain binding?
Yes, ligustilide covalently binds the MH2 domain of Smad3 and disrupts the Smad3-SARA interaction, attenuating airway remodeling in COPD mice.
What is the structure of the MH2 domain?
The crystal structure of the MH2 domain of Drosophila Mad has been determined, and the structure of human TGIF1 bound to the SMAD2 MH2 domain has provided insights into binding specificity.
How can CRISPR be used to study MH2 domain binding?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to test causal roles of MH2 domain-containing proteins and their binding partners in signaling and disease.
What methods are used to study MH2 domain binding?
Common methods include X-ray crystallography, co-immunoprecipitation, reporter assays, affinity purification-mass spectrometry, and CRISPR-based perturbation.
Why is MH2 domain binding important for cancer research?
It controls TGF-β signaling output, which influences proliferation and plasticity; dysregulation has been implicated in cholangiocarcinoma, liver cancer, and breast cancer.
Conclusion
GO:0035500 (MH2 domain binding) defines a central interaction function in TGF-β superfamily signaling, where the MH2 domain of Smad proteins recruits diverse partners and supports oligomerization. Experimental evidence links this function to fibrosis, COPD, and multiple cancers through proteins such as PKM2, SMAD3, SMAD4, AMDHD1, and pVHL. Structural and CRISPR-based studies provide complementary routes to dissect and target these interactions.
References
- 1. Gao S et al.. 2022. PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling.. Sci Adv 8(38):eabo0987 PMID: 36129984
- 2. Zhou H et al.. 2025. Structural insights into the binding of human TGIF1 with SMAD2 MH2 domain.. FEBS Lett PMID: 40395157
- 3. Lu YJ et al.. 2023. Ligustilide attenuates airway remodeling in COPD mice by covalently binding to MH2 domain of Smad3 in pulmonary epithelium, disrupting the Smad3-SARA interaction.. Phytother Res 37(2):717-730 PMID: 36216328
- 4. Ma Z et al.. 2025. AMDHD1 acts as a tumor suppressor and contributes to activation of TGF-β signaling pathway in cholangiocarcinoma.. Cell Death Differ 32(1):162-176 PMID: 39143229
- 5. Chaomin W et al.. 2022. Spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation in hepatitis B-related liver cancer.. Cell Oncol (Dordr) 45(4):573-589 PMID: 35716259
- 6. Fan C et al.. 2025. SMAD3 and p300 complex scaffolding by long non-coding RNA LIMD1-AS1 promotes TGF-β-induced breast cancer cell plasticity.. Nucleic Acids Res 53(16) PMID: 40889156
- 7. Zhou J et al.. 2022. pVHL-mediated SMAD3 degradation suppresses TGF-β signaling.. J Cell Biol 221(1) PMID: 34860252
- 8. WANG C et al.. 2009. Crystal structure of the MH2 domain of Drosophila Mad.. Sci China C Life Sci 52(6):539-44 PMID: 19557331
